Chronic high-dose glycine nutrition: Effects on rat brain cell morphology

Biological Psychiatry

Volumn 49, Issue 10, 2001, Pages 876-885

  Shoham, Shai ^a   Javitt, Daniel C ^c,d   Heresco Levy, Uriel ^a,b  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Calcium channels; Glycine; Neurotoxicity; NMDA receptor; Schizophrenia

Indexed keywords

CALCIUM CHANNEL N TYPE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCINE; MICROTUBULE ASSOCIATED PROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD LEVEL; BRAIN CELL; BRAIN REGION; CELL STRUCTURE; CONTROLLED STUDY; DENTATE GYRUS; DRUG MEGADOSE; GLIA CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NERVE DEGENERATION; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; SCHIZOPHRENIA; SILVER IMPREGNATION; TREATMENT OUTCOME;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIBODIES, MONOCLONAL; ASTROCYTES; BRAIN; CALCIUM CHANNELS; CELL COUNT; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCINE; HIPPOCAMPUS; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALE; PARIETAL LOBE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0035873734     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01046-5     Document Type: Article

References (54)

1. Baker AJ, Zernon MH, Sheller MS, Yaksht L, Skilling SR, Smullin DH, et al (1991): Changes in extracellular concentration of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J Neurochem 57:1370-1379.
2. Bernardis LL, Bellinger LL (1996): The lateral hypothalamic area revisited: Ingestive behavior. Neurosci Biobehav Rev 20:189-287.
3. Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, Olney JW (1997): Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res 572:1-14.
4. Cotman CW, Monaghan DT, Ganong AH (1988): Excitatory amino acids and neurotransmission: NMDA receptor and Hebb-type synaptic plasticity. Annu Rev Neurosci 11:61-80.
5. Coyle JT, Puttfarcken P (1993): Oxidative stress, glutamate and neurodegenerative disorders. Science 262:689-695.
6. D'Souza DC, Charney D, Krystal J (1995): Glycine site agonists of the NMDA receptor: A review. CNS Drug Rev 1:227-260.
7. Dubel SJ, Starr TV B, Hell J, Ahlijanian MK, Enyeart JJ, Catterall WA, Snutch TP (1992): Molecular cloning of the α-1-subunit of an ω-connotoxin-sensitive calcium channel. Proc Natl Acad Sci USA 89:5058-5062.
8. Elliott EM, Malouf AT, Catterall WA (1995): Role of calcium channel subtypes in calcium transients in hippocampal CA3 neurons. J Neurosci 10:6433-6444.
9. 3H) GLY uptake in rat hippocampus: Kinetic analysis and autoradiographic localization. Brain Res 572:154-163.
10. Gallyas F, Guldner FH, Zoltay G, Wolff JR (1990): Golgi-like demonstration of "dark" neurons with an argyrophilia. Ill method for experimental neuropathology. Acta Neuropathol (Berl) 79:620-628.
11. Globus MYT, Ginsberg MD, Busto R (1991): Excitotoxicity index - a biochemical marker of selective vulnerability. Neurosci Lett 127:39-42.
12. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al (1999): A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21-27.
13. Harihararn M, Naga S, VanNoord T (1993): Systematic approach to the development of plasma amino acid analysis by high-performance liquid chromatography with ultraviolet detection with precolumn derivatization using phenyl isothiocyanate. J Chromatogr 621:15-22.
14. Heresco-Levy U, Javitt DC (1998): The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 8:141-152.
15. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999): Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36.
16. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998): Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1:131-137.
17. Heresco-Levy U, Silipo G, Javitt DC (1996): Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 32:731-740.
18. Huettner JE (1991): Competitive antagonism of glycine at the N-methyl-D-aspartate (NMDA) receptor. Biochem Pharmacol 41:9-16.
19. Javitt DC, Balla A, Sershen H, Lajtha A (1999): Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45:668-679.
20. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
21. Johnson JW, Asher P (1987): Glycine potentiates the NMDA responses in cultured mouse brain neurons. Nature 325:529-531.
22. Kanai Y, Smith CP, Hediger MA (1993): The elusive transporters with a high affinity for glutamate. Trends Neurosci 16:359-365.
23. Kleckner NW, Dingledine R (1988): Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835-837.
24. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
25. Lahti AC, Koffel B, Laporte D, Tamminga CA (1995): Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
26. Lawlor B A, Davis KL (1992): Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 31:337-350.
27. Lehman J, Colpaert F, Canton H (1991): Glutamate and glycine co-activate while polyamines merely modulate the NMDA receptor complex. Prog Neuropsychopharmacol Biol Psychiatry 15:188-199.
28. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC (1996): Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open label trial. Biol Psychiatry 39:213-215.
29. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R (1959): Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 81:363-369.
30. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al (1997): Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150.
31. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al (1996): NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
32. Mangano TJ, Patel J, Salama AI, Keith RA (1990): Glycine-evoked neurotransmitter release from rat hippocampal brain slices: Evidence for the involvement of glutaminergic transmission. J Pharmacol Exp Ther 252:374-380.
33. Muir KW, Lees KR (1995): Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513.
34. Nakajima K, Kohsaka S (1993): Functional roles of microglia in the brain. Neurosci Res 17:187-203.
35. Newell DW, Barth A, Ricciardi TN, Malouf AT (1997): Glycine causes increased excitability and neurotoxicity by activation of NMDA receptors in the hippocampus. Exp Neurol 165:235-244.
36. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988): Glutamate becomes neurotoxic via N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205-212.
37. Ogura H, Furuya Y, Teramoto T, Niidome T, Nishizawa Y, Yamanishi Y (1998): Peptide N- and P/Q-type CA2+ blockers inhibit stimulant-induced hyperactivity in mice. Peptides 19:1017-1022.
38. Oldendorph WM (1971): Brain uptake of radio labeled amino acids, amines and hexoses after arterial injection. Am J Physiol 224:1629-1639.
39. Olney JW (1989): Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26:505-525.
40. Olney JW (1994): New mechanisms of excitatory transmitter neurotoxicity. J Neural Transm Suppl 43:47-51.
41. Sato K, Yoshida S, Fujiwara K, Tada K, Tohyama M (1991): Glycine cleavage system in astrocytes. Brain Res 567:64-70.
42. Shao Y, McCarthy KD (1994): Plasticity of astrocytes. Glia 11:147-155.
43. Shoham S, Javitt DC, Heresco-Levy U (1998): Morphological effects of high-dose glycine nutrition in rat brain. Isr J Psychiatry 35(suppl). PSII11
44. Shoham S, Javitt DC, Heresco-Levy U (1999): High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum. Int J Neuropsychopharmacol 2:35-40.
45. Sirevaag AM, Black JR, Greenough WT (1991): Astrocyte hypertrophy in the dentate gyrus of young male rats reflects variation of individual stress rather than group environmental complexity manipulations. Exp Neurol 111:74-79.
46. Steward O, Halpain S (1999): Lamina-specific synaptic activation causes domain-specific alterations in dendritic immunostaining for MAP2 and CAM kinase II. J Neurosci 19:7834-7845.
47. Supplisson S, Bergman C (1997): Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 17:4580-4590.
48. Toth E, Lajtha A (1986): Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11:393-400.
49. Trojanowski JQ, Walkenstein N, Lee VM (1986): Expression of neurofilament subunits in neurons of the central and peripheral nervous system: An immunohistochemical study with monoclonal antibodies. J Neurosci 6:650-660.
50. Tsai G, Yong P, Chung L-C, Lange N, Coyle JT (1998): D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089.
51. Tsai GE, Young PJ, Coyle JT (1999): D-Alanine treatment of schizophrenia. Paper presented at the 38th Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico.
52. Waziri R (1996): Glycine therapy of schizophrenia: Some caveats. Biol Psychiatry 39:155-156.
53. Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA (1992): Biochemical properties and subcellular distribution of an N-type calcium channel al subunit. Neuron 9:1099-1115.
54. Yasuda H, Kinoshita S, Tsumoto T (1998): Localized contribution of N-methyl-D-aspartate receptors to synaptic input-induced rise of calcium in apical dendrites of layer II/III neurons in rat visual cortex. Neuroscience 85:1011-1024.